Browse our 650+ Publications​

Latest Publications

Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients

Xydia M., et al.
Nature Communications
February 2021
Authors and Affiliates
Maria Xydia 1,2, Raheleh Rahbari 3, Eliana Ruggiero 4, Iain Macaulay 3,5, Maxime Tarabichi 3,6, Robert Lohmayer 7,8, Stefan Wilkening 4, Tillmann Michels 7, Daniel Brown 9,10, Sebastiaan Vanuytven 6,9, Svetlana Mastitskaya 11,12, Sean Laidlaw 3, Niels Grabe 11,13, Maria Pritsch 14, Raffaele Fronza 4, Klaus Hexel 15, Steffen Schmitt 15, Michael Müller-Steinhardt 16, Niels Halama 11,13, Christoph Domschke 17, Manfred Schmidt 4, Christof von Kalle 4,18, Florian Schütz 17, Thierry Voet 3,9, Philipp Beckhove 19,20; 1 RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg, Regensburg, Germany. Maria.Xydia@ukr.de. 2 Translational Immunology Department, German Cancer Research Centre, Heidelberg, Germany. Maria.Xydia@ukr.de. 3 The Cancer, Ageing and Somatic Mutation Program, Wellcome Sanger Institute, Hinxton, UK. 4 Translational Oncology Department, National Centre for Tumor Diseases and German Cancer Research Centre, Heidelberg, Germany. 5 Technical Development, Earlham Institute, Norwich, UK. 6 The Francis Crick Institute, London, UK. 7 RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg, Regensburg, Germany. 8 Institute for Theoretical Physics, University of Regensburg, Regensburg, Germany. 9 Department of Human Genetics, University of Leuven, KU Leuven, Leuven, Belgium. 10 The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. 11 Medical Oncology Department, National Centre for Tumor Diseases, Heidelberg, Germany. 12 Centre for Cardiovascular and Metabolic Neuroscience, Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK. 13 Hamamatsu Tissue Imaging and Analysis Centre, BIOQUANT, University of Heidelberg, Heidelberg, Germany. 14 Translational Immunology Department, German Cancer Research Centre, Heidelberg, Germany. 15 Flow Cytometry Core Facility, German Cancer Research Centre, Heidelberg, Germany. 16 German Red Cross (DRK Blood Donation Service in Baden-Württemberg-Hessen) and Institute for Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 17 Department of Gynecology and Obstetrics, University Hospital of Heidelberg, Heidelberg, Germany. 18 Clinical Study Centre, Charité/BIH, Berlin, Germany. 19 RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg, Regensburg, Germany. beckhove@rcii.de. 20 Translational Immunology Department, German Cancer Research Centre, Heidelberg, Germany. beckhove@rcii.de.

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

Duhen R., et al.
Nature Communications
February 2021
Authors and Affiliates
Rebekka Duhen 1, Carmen Ballesteros-Merino 2, Alexandra K Frye 2, Eric Tran 2, Venkatesh Rajamanickam 2, Shu-Ching Chang 3, Yoshinobu Koguchi 2, Carlo B Bifulco 2,4, Brady Bernard 2, Rom S Leidner 2, Brendan D Curti 2, Bernard A Fox 2, Walter J Urba 2, R Bryan Bell 2, Andrew D Weinberg 5,6; 1 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. rebekka.duhen@providence.org. 2 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. 3 Medical Data Research Center, Providence Saint Joseph's Health, Portland, OR, USA. 4 Molecular Genomics Laboratory, Providence St. Joseph Health, Portland, OR, USA. 5 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. andrew.weinberg@providence.org. 6 AgonOx, Inc., Portland, OR, USA. andrew.weinberg@providence.org.

T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective

Meier JA., et al.
Biology of Blood and Marrow Transplantation
February 2021
Authors and Affiliates
Jeremy A Meier 1, Mahdee Haque 1, Mohamed Fawaz 1, Hamdi Abdeen 1, David Coffey 2, Andrea Towlerton 2, Ahmed Abdeen 1, Abdullah Toor 1, Edus Warren 2, Jason Reed 3, Christopher G Kanakry 4, Armand Keating 5, Leo Luznik 6, Amir A Toor 7; 1 Bone Marrow Transplant Program, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. 2 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 3 Department of Physics, Virginia Commonwealth University, Richmond, Virginia. 4 Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 5 Princess Margaret Cancer Center, Toronto, Ontario, Canada. 6 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 7 Bone Marrow Transplant Program, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. Electronic address: amir.toor@vcuhealth.org

In chronic infection, HIV gag-specific CD4+ T cell receptor diversity is higher than CD8+ T cell receptor diversity and is associated with less HIV quasispecies diversity

Pilkinton MA., et al.
Journal of Virology
February 2021
Authors and Affiliates
Mark A Pilkinton 1, Wyatt J McDonnell 1, Louise Barnett 1, Abha Chopra 2, Rama Gangula 1, Katie D White 1, Shay Leary 2, Jennifer Currenti 3, Silvana Gaudieri 1,2,3, Simon A Mallal 1,2,4, Spyros A Kalams 5,4; 1 Vanderbilt University Medical Center, Department of Internal Medicine, Nashville, TN 38232. 2 Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia. 3 School of Human Sciences, University of Western Australia, Nedlands, Australia. 4 Vanderbilt University School of Medicine, Department of Pathology, Microbiology and Immunology, Nashville, TN 38232. 5 Vanderbilt University Medical Center, Department of Internal Medicine, Nashville, TN 38232 s.kalams@vumc.org

Safety and Clinical Activity of Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer: a Phase I Study

Petrylak DP., et al.
Clinical Cancer Research
February 2021
Authors and Affiliates
Daniel P Petrylak 1, Yohann Loriot 2, David Shaffer 3, Fadi Braiteh 4, John Powderly 5, Lauren C Harshman 6, Paul Conkling 7, Jean-Pierre Delord 8, Michael Gordon 9, Joseph W Kim 10, Indrani Sarkar 11, Kobe C Yuen 12, Edward E Kadel 13, Sanjeev Mariathasan 14, Carol O'Hear 11, Sujata Narayanan 11, Marcella Fassò 15, Susheela Carroll 16, Thomas Powles 17; 1 Prostate and Urologic Cancers Program, Yale Cancer Center daniel.petrylak@yale.edu. 2 Vancouver Prostate Centre, Gustave Roussy, INSERM U981. 3 Medicine, New York Oncology Hematology. 4 Translational Oncology Program, Comprehensive Cancer Centers of Nevada. 5 Oncology, Carolina BioOncology Institute. 6 Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute. 7 Virginia Oncology Associates, US Oncology Phase I Group. 8 Clinical Research Unit, Institut Claudius Regaud, IUCT-Oncopole. 9 HonorHealth Research Institute. 10 Department of Medicine, Yale University. 11 Genentech, Inc. 12 Oncology Biomarker Development, Genentech. 13 Oncology Biomarker Development, Genentech, Inc. 14 Genentech. 15 PDO, Genentech, Inc. 16 Clinical Science, Genentech, Inc. 17 Experimental Cancer Medicine Centre, Queen Mary University of London.

αβγδ T cells play a vital role in fetal human skin development and immunity

Reitermaier R., et al.
Journal of Experimental Medicine
February 2021
Authors and Affiliates
René Reitermaier 1, Thomas Krausgruber 2, Nikolaus Fortelny 2, Tanya Ayub 1, Pablo Augusto Vieyra-Garcia 3, Philip Kienzl 1, Peter Wolf 3, Anke Scharrer 4, Christian Fiala 5,6, Marita Kölz 4, Manuela Hiess 7, Martin Vierhapper 8, Christopher Schuster 1, Andreas Spittler 9, Christof Worda 10, Wolfgang Weninger 1, Christoph Bock 2,11, Wolfgang Eppel 10, Adelheid Elbe-Bürger 1; 1 Department of Dermatology, Medical University of Vienna, Vienna, Austria. 2 Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria. 3 Department of Dermatology, Medical University of Graz, Graz, Austria. 4 Department of Pathology, Medical University of Vienna, Vienna, Austria. 5 Gynmed Clinic, Vienna, Austria. 6 Department of Women's and Children's Health, Division of Obstetrics and Gynaecology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden. 7 Department of Urology, Medical University of Vienna, Vienna, Austria. 8 Department of Surgery, Division of Plastic and Reconstructive Surgery, Medical University of Vienna, Vienna, Austria. 9 Core Facilities, Flow Cytometry, Medical University of Vienna, Vienna, Austria. 10 Department of Obstetrics & Gynecology, Medical University of Vienna, Vienna, Austria. 11 Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Diagnosis and Tracking of SARS-CoV-2 Infection By T-Cell Receptor Sequencing

Gittelman RM., et al.
February 2021
Authors and Affiliates
Rachel M. Gittelman 1, Enrico Lavezzo 2, Thomas M. Snyder 1, H. Jabran Zahid 3, Rebecca Elyanow 1, Sudeb Dalai 1,4, Ilan Kirsch 1, Lance Baldo 1, Laura Manuto 2, Elisa Franchin 2, Claudia Del Vecchio 2, Monia Pacenti 5, Caterina Boldrin 5, Margherita Cattai 5, Francesca Saluzzo 2, Andrea Padoan 6, Mario Plebani 6, Fabio Simeoni 7, Jessica Bordini 8, Nicola I. Lorè 9, Dejan Lazarevic 7, Daniela M. Cirillo 9, Paolo Ghia 8,10, Stefano Toppo 2,11, Jonathan M. Carlson 3, Harlan S. Robins 1, Giovanni Tonon 7,8, Andrea Crisanti 2,12; 1 Adaptive Biotechnologies, Seattle, WA, USA 2 Department of Molecular Medicine, University of Padova, Padua, Italy 3 Microsoft Research, Redmond, WA, USA 4 Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine 5 Azienda Ospedale Padova, Microbiology and Virology Unit, Padua, Italy 6 Department of Medicine, University of Padova, Padua, Italy 7 Center for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy 8 Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy 9 Division of Immunology, Transplantation and Infectious Disease, IRCCS Ospedale San Raffaele, Milan, Italy 10 Università Vita- Salute San Raffaele, Milan, Italy 11 CRIBI Biotech Center, University of Padova, Padua, Italy 12 Department of Life Sciences, Imperial College London, London, UK

Safety, anti-tumor activity and T-cell responses in a dose-ranging phase 1 trial of the oncolytic peptide LTX-315 in patients with solid tumors

Spicer J., et al.
Clinical Cancer Research
February 2021
Authors and Affiliates
James Spicer 1, Aurelien Marabelle 2, Jean-Francois Baurain 3, Nina Louise Jebsen 4, Dag Eirik Jøssang 5, Ahmad Awada 6, Rebecca Kristeleit 7, Delphine Loirat 8, George Lazaridis 9, Christiane Jungels 10, Paal Brunsvig 11, Berit Nicolaisen 12, Andrew Saunders 13, Hamina Patel 13, Jerome Galon 14, Fabienne Hermitte 15, Ketil André Camilio 13, Brynjar Mauseth 13, Vibeke Sundvold 16, Baldur Sveinbjørnsson 17, Øystein Rekdal 13; 1 School Cancer & Pharmacological Sciences, King's College London james.spicer@kcl.ac.uk. 2 Institut Gustave Roussy. 3 King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc. 4 Centre for Cancer Biomarkers, Dep. of Clinical Science and Dep. of Oncology, University of Bergen and Haukeland University Hospital, Bergen. 5 Haukeland University Hospital. 6 Oncology Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles. 7 Dept of Oncology, Guy's and St Thomas' NHS Foundation Trust. 8 Medical Oncology, Institute Curie. 9 Guy's Hospital, King's College London. 10 Department of Medical Oncology, Institut Jules Bordet. 11 Oslo University Hospital. 12 Medical, Lytix Biopharma AS. 13 Lytix Biopharma AS. 14 Inserm U1138, Laboratory of Integrative Cancer Immunology. 15 Medical Affairs, HalioDx, Marseille, France. 16 Biopharma, Lytix Biopharma (Norway). 17 Cell Biology and Histology, University of Norway.

A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

Nowicki NS., et a.
Clinical Cancer Research
February 2021
Authors and Affiliates
Theodore S Nowicki 1, Beata Berent-Maoz 2, Gardenia Cheung-Lau 2, Rong Rong Huang 3, Xiaoyan Wang 4, Jennifer Tsoi 2, Paula Kaplan-Lefko 2, Paula Cabrera 2, Justin Tran 2, Jia Pang 2, Mignonette Macabali 2, Ivan Perez Garcilazo 2, Ignacio Baselga Carretero 2, Anusha Kalbasi 5,6,7, Alistair J Cochran 3, Catherine S Grasso 2, Siwen Hu-Lieskovan 2, Bartosz Chmielowski 2, Begoña Comin-Anduix 6,7, Arun Singh 8, Antoni Ribas 8,6,7,9,10; 1 Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California. 2 Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California. 3 Department of Pathology, University of California Los Angeles, Los Angeles, California. 4 Department of General Internal Medicine and Health Services Research, University of California Los Angeles, Los Angeles, California. 5 Division of Molecular and Cellular Oncology, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California. 6 Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California. 7 Division of Surgical-Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California. 8 Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California. asingh@mednet.ucla.edu aribas@mednet.ucla.edu. 9 Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, California. 10 Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients

Amini L., et al.
Molecular Therapy
February 2021
Authors and Affiliates
Leila Amini 1, Dimitrios Laurin Wagner 2, Uta Rössler 3, Ghazaleh Zarrinrad 4, Livia Felicitas Wagner 5, Tino Vollmer 6, Désirée Jacqueline Wendering 7, Uwe Kornak 3, Hans-Dieter Volk 1, Petra Reinke 2, Michael Schmueck-Henneresse 8; 1 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 2 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 3 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Institute of Medical Genetics and Human Genetics, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 4 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Einstein Center for Regenerative Therapies, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 5 Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 6 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 7 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 8 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. Electronic address: michael.schmueck-henneresse@charite.de.
Previous Next